BRD4 inhibitor IBET upregulates p27kip/cip protein stability in neuroendocrine tumor cells

References

• Kulke M. Advances in the treatment of neuroendocrine tumors. Curr Treat Options Oncol 2005; 6:397-409; PMID:16107243; http://dx.doi.org/10.1007/s11864-005-0043-9
   PubMedGoogle Scholar
• Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008; 135:1469-92; PMID:18703061; http://dx.doi.org/10.1053/j.gastro.2008.05.047
   PubMed Web of Science ®Google Scholar
• Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, et al. One hundred years after “carcinoid:” epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26:3063-72; PMID:18565894; http://dx.doi.org/10.1200/JCO.2007.15.4377
   PubMed Web of Science ®Google Scholar
• Leotlela PD, Jauch A, Holtgreve-Grez H, Thakker RV. Genetics of neuroendocrine and carcinoid tumours. Endocr Relat Cancer 2003; 10:437-50; PMID:14713256; http://dx.doi.org/10.1677/erc.0.0100437
   PubMed Web of Science ®Google Scholar
• Eigler T, Ben-Shlomo A. Somatostatin system: molecular mechanisms regulating anterior pituitary hormones. J Mol Endocrinol 2014; 53:R1-19; PMID:24780840; http://dx.doi.org/10.1530/JME-14-0034
   PubMed Web of Science ®Google Scholar
• Strosberg JR, Kvols LK. A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours. Expert Opin Investig Drugs 2007; 16:219-24; PMID:17243941; http://dx.doi.org/10.1517/13543784.16.2.219
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:514-23; PMID:21306238; http://dx.doi.org/10.1056/NEJMoa1009290
   PubMed Web of Science ®Google Scholar
• Fine RL, Gulati AP, Krantz BA, Moss RA, Schreibman S, Tsushima DA, Mowatt KB, Dinnen RD, Mao Y, Stevens PD, et al. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol 2013; 71:663-70; PMID:23370660; http://dx.doi.org/10.1007/s00280-012-2055-z
   PubMed Web of Science ®Google Scholar
• Wang GG, Song J, Wang Z, Dormann HL, Casadio F, Li H, Luo JL, Patel DJ, Allis CD. Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature 2009; 459(7248):847-51; PMID:19430464; http://dx.doi.org/10.1038/nature08036
   PubMed Web of Science ®Google Scholar
• Wu X, Hua X. Menin, histone h3 methyltransferases, and regulation of cell proliferation: current knowledge and perspective. Curr Mol Med 2008; 8:805-15; PMID:19075677; http://dx.doi.org/10.2174/156652408786733702
   PubMedGoogle Scholar
• Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146:904-17; PMID:21889194; http://dx.doi.org/10.1016/j.cell.2011.08.017
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et al. Selective inhibition of BET bromodomains. Nature 2010; 468:1067-73; PMID:20871596; http://dx.doi.org/10.1038/nature09504
   PubMed Web of Science ®Google Scholar
• Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011; 478:524-8; PMID:21814200; http://dx.doi.org/10.1038/nature10334
   PubMed Web of Science ®Google Scholar
• Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, Robson SC, Chung CW, Hopf C, Savitski MM, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011; 478:529-33; PMID:21964340; http://dx.doi.org/10.1038/nature10509
   PubMed Web of Science ®Google Scholar
• Wong C, Laddha SV, Tang L, Vosburgh E, Levine AJ, Normant E, Sandy P, Harris CR, Chan CS, Xu EY. The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors. Cell Death Dis 2014; 5:e1450; PMID:25299775; http://dx.doi.org/10.1038/cddis.2014.396
   PubMed Web of Science ®Google Scholar
• Evers BM, Ishizuka J, Townsend CM Jr, Thompson JC. The human carcinoid cell line, BON. A model system for the study of carcinoid tumors. Ann N Y Acad Sci 1994; 733:393-406; PMID:7978888; http://dx.doi.org/10.1111/j.1749-6632.1994.tb17289.x
   PubMed Web of Science ®Google Scholar
• Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000; 60:3689-95; PMID:10919634
   PubMed Web of Science ®Google Scholar
• Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S, Su L, Xiong Y. CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev 1998; 12:2899-911; PMID:9744866; http://dx.doi.org/10.1101/gad.12.18.2899
   PubMed Web of Science ®Google Scholar
• Karnik SK, Hughes CM, Gu X, Rozenblatt-Rosen O, McLean GW, Xiong Y, Meyerson M, Kim SK. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc Natl Acad Sci U S A 2005; 102:14659-64; PMID:16195383; http://dx.doi.org/10.1073/pnas.0503484102
   PubMed Web of Science ®Google Scholar
• Milne TA, Hughes CM, Lloyd R, Yang Z, Rozenblatt-Rosen O, Dou Y, Schnepp RW, Krankel C, Livolsi VA, Gibbs D, et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci U S A 2005; 102:749-54; PMID:15640349; http://dx.doi.org/10.1073/pnas.0408836102
   PubMed Web of Science ®Google Scholar
• Medema RH, Kops GJ, Bos JL, Burgering BM. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 2000; 404:782-7; PMID:10783894; http://dx.doi.org/10.1038/35008115
   PubMed Web of Science ®Google Scholar
• Nakayama K, Nagahama H, Minamishima YA, Miyake S, Ishida N, Hatakeyama S, Kitagawa M, Iemura S, Natsume T, Nakayama KI. Skp2-mediated degradation of p27 regulates progression into mitosis. Dev Cell 2004; 6:661-72; PMID:15130491; http://dx.doi.org/10.1016/S1534-5807(04)00131-5
   PubMed Web of Science ®Google Scholar
• Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011; 331:1199-203; PMID:21252315; http://dx.doi.org/10.1126/science.1200609
   PubMed Web of Science ®Google Scholar
• Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27:4656-63; PMID:19704057; http://dx.doi.org/10.1200/JCO.2009.22.8510
   PubMed Web of Science ®Google Scholar
• Nagashima T, Shigematsu N, Maruki R, Urano Y, Tanaka H, Shimaya A, Shimokawa T, Shibasaki M. Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db/db mice. Mol Pharmacol 2010; 78:961-70; PMID:20736318; http://dx.doi.org/10.1124/mol.110.065714
   PubMed Web of Science ®Google Scholar
• Schneider-Poetsch T, Ju J, Eyler DE, Dang Y, Bhat S, Merrick WC, Green R, Shen B, Liu JO. Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin. Nat Chem Biol 2010; 6:209-17; PMID:20118940; http://dx.doi.org/10.1038/nchembio.304
   PubMed Web of Science ®Google Scholar
• Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014; 25:282-303; PMID:24651011; http://dx.doi.org/10.1016/j.ccr.2014.02.025
   PubMed Web of Science ®Google Scholar
• Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003; 112:831-43; PMID:12654249; http://dx.doi.org/10.1016/S0092-8674(03)00190-9
   PubMed Web of Science ®Google Scholar
• Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011; 19:58-71; PMID:21215704; http://dx.doi.org/10.1016/j.ccr.2010.10.031
   PubMed Web of Science ®Google Scholar
• Matkar S, Sharma P, Gao S, Gurung B, Katona BW, Liao J, Muhammad AB, Kong XC, Wang L, Jin G, et al. An epigenetic pathway regulates sensitivity of breast cancer cells to HER2 inhibition via FOXO/c-Myc axis. Cancer cell 2015; 28:472-85; PMID:26461093; http://dx.doi.org/10.1016/j.ccell.2015.09.005
   PubMed Web of Science ®Google Scholar
• Li GQ, Guo WZ, Zhang Y, Seng JJ, Zhang HP, Ma XX, Zhang G, Li J, Yan B, Tang HW, et al. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression. Oncotarget 2016; 7:2462-74; PMID:26575167; http://dx.doi.org/10.18632/oncotarget.6275
   PubMed Web of Science ®Google Scholar
• Segura MF, Fontanals-Cirera B, Gaziel-Sovran A, Guijarro MV, Hanniford D, Zhang G, González-Gomez P, Morante M, Jubierre L, Zhang W, et al. BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. Cancer Res 2013; 73:6264-76; PMID:23950209; http://dx.doi.org/10.1158/0008-5472.CAN-13-0122-T
   PubMed Web of Science ®Google Scholar
• He X, Wang L, Yan J, Yuan C, Witze ES, Hua X. Menin localization in cell membrane compartment. Cancer Biol Ther 2016; 17:114-22; PMID:26560942; http://dx.doi.org/10.1080/15384047.2015.1108497
   PubMed Web of Science ®Google Scholar